Management of glaucoma in pregnancy - balancing safety with efficacy
- PMID: 34263134
- PMCID: PMC8243098
- DOI: 10.1177/25158414211022876
Management of glaucoma in pregnancy - balancing safety with efficacy
Abstract
Glaucoma and pregnancy is an uncommon combination, but it constitutes a very challenging situation for the treating doctor. The challenge is not only controlling the intraocular pressure and preventing glaucoma progression in the mother, but also having to deal with her mental stress and anxiety regarding the safety of her child. The situation is further worsened by the lack of definite guidelines as to how to deal with such patients. Relative rarity of glaucoma in this population restricts any large prospective randomized clinical trials or any large systematic studies. Moreover, none of the existing anti-glaucoma medications is absolutely safe in pregnancy. Current practice patterns depend on some case reports, a few observational studies and a few animal studies that attempt at determining the safety and efficacy of the available medicines. These are then prescribed on the basis of their relative safety in any particular stage of pregnancy or lactation. Newer medications that were released recently in 2018, such as Vyzulta and Rhopressa, presently have limited data to support their safety for use during pregnancy. Laser trabeculoplasty, conventional filtration surgery (of course without anti-metabolites), and minimally invasive glaucoma surgery represent a few non-pharmacological management options. Surgical procedures such as trabeculectomy and tube-shunts or collagen matrix implants, and newer minimally invasive glaucoma surgery procedures such as the gelatin stents are currently being explored and may prove to be viable solutions for severe glaucoma during pregnancy, although they too have their own inherent drawbacks. Management of glaucoma during pregnancy and lactation requires careful consideration of the disease status, gestational stage, US Food and Drug Administration classification and guidelines, and potential benefits and limitations of the various therapeutic modalities. This review focuses on the importance of a multidisciplinary team approach, starting with preconception planning and counseling, determining the treatment options depending on the stage of glaucoma and of pregnancy, and emphasizes the involvement of the patients, their obstetrician, and pediatrician through active discussion regarding the various medical, laser, or surgical modalities currently available or under exploration for use during pregnancy and lactation. The ultimate aim is to achieve an optimal balance between the risks and benefits of any type of intervention, and to customize treatment on an individual basis in order to achieve the best outcomes for both mother and fetus.
Keywords: Rhopressa; Vyzulta; XEN Gel Implant; anti-glaucoma medications; glaucoma in pregnancy; glaucoma surgery in pregnancy; iridoplasty; laser iridotomy; laser surgeries in pregnancy; laser trabeculoplasty.
© The Author(s), 2021.
Conflict of interest statement
Conflict of interest statement: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Figures
Similar articles
-
Glaucoma in pregnancy: an update.Curr Opin Ophthalmol. 2020 Mar;31(2):114-122. doi: 10.1097/ICU.0000000000000641. Curr Opin Ophthalmol. 2020. PMID: 31922978 Review.
-
Glaucoma in pregnancy.Curr Opin Ophthalmol. 2014 Mar;25(2):93-7. doi: 10.1097/ICU.0000000000000029. Curr Opin Ophthalmol. 2014. PMID: 24469077 Review.
-
Trabeculectomy in pregnancy: Case studies and literature review.Indian J Ophthalmol. 2020 Mar;68(3):420-426. doi: 10.4103/ijo.IJO_638_19. Indian J Ophthalmol. 2020. PMID: 32056993 Free PMC article. Review.
-
Laser peripheral iridoplasty for chronic angle closure.Cochrane Database Syst Rev. 2021 Mar 23;3(3):CD006746. doi: 10.1002/14651858.CD006746.pub4. Cochrane Database Syst Rev. 2021. PMID: 33755197 Free PMC article.
-
Cyclodestructive procedures for refractory glaucoma.Cochrane Database Syst Rev. 2019 Mar 10;3(3):CD012223. doi: 10.1002/14651858.CD012223.pub2. Cochrane Database Syst Rev. 2019. PMID: 30852841 Free PMC article.
Cited by
-
[Ophthalmic agents during pregnancy].Ophthalmologie. 2024 Apr;121(4):333-348. doi: 10.1007/s00347-024-02025-5. Epub 2024 Apr 8. Ophthalmologie. 2024. PMID: 38587538 Review. German.
-
Advancing Glaucoma Treatment During Pregnancy and Breastfeeding: Contemporary Management Strategies and Prospective Therapeutic Developments.Biomedicines. 2024 Nov 25;12(12):2685. doi: 10.3390/biomedicines12122685. Biomedicines. 2024. PMID: 39767592 Free PMC article. Review.
-
Outcomes of pregnancy after exposure to antiglaucoma drugs.Indian J Ophthalmol. 2024 Apr 1;72(4):599-601. doi: 10.4103/IJO.IJO_3231_23. Epub 2024 Mar 28. Indian J Ophthalmol. 2024. PMID: 38546472 Free PMC article. No abstract available.
-
A State-of-the-Art Review of Ophthalmological Indications for a Cesarean Section: Is There a Patient for Whom a Cesarean Section Is Really Indicated?Diagnostics (Basel). 2025 Feb 9;15(4):418. doi: 10.3390/diagnostics15040418. Diagnostics (Basel). 2025. PMID: 40002569 Free PMC article. Review.
-
Latanoprostene bunod: the first nitric oxide-donating antiglaucoma medication.Med Gas Res. 2025 Jun 1;15(2):220-227. doi: 10.4103/mgr.MEDGASRES-D-24-00023. Epub 2024 Dec 7. Med Gas Res. 2025. PMID: 39829161 Free PMC article. Review.
References
-
- Tham Y-C, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040. Ophthalmology 2014; 121: 2081–2090. - PubMed
-
- Colãs-Tomãs T, López Tizón E. Ex-PRESS mini-shunt implanted in a pregnant patient with iridocorneal endothelial syndrome. Eur J Ophthalmol 2020; 30: NP25–NP28. - PubMed
-
- Vaideanu D, Fraser S. Glaucoma management in pregnancy: a questionnaire survey. Eye (Lond) 2007; 21: 341–343. - PubMed
Publication types
LinkOut - more resources
Full Text Sources